Table 2.
Association between the market entry of biosimilar filgrastim and patient out-of-pocket costs for branded filgrastim products
| Change in Average Patient Out-of-Pocket Cost for 480 mcg of Branded Filgrastim (in U.S. Dollars a) | ||
|---|---|---|
| Level Change b | Slope Change c | |
| All Branded Filgrastim products, Estimate, (95% CI) | −0.20 (−5.29: 4.90) | −0.08 (−0.41: 0.24) |
| By Health Plan Type Estimate, (95% CI) | ||
| PPO | −2.58 (−8.43: 3.27) | 0.02 (−0.36: 0.39) |
| HDHP | 0.81 (−6.94: 8.56) | −0.59 (−1.03: −0.14) * |
| CDHP | −3.81 (−13.93: 6.31) | −0.79 (−1.38: −0.19) * |
Abbreviations: PPO: Preferred Provider Organization, HDHP: high deductible health plan, CDHP: consumer directed health plan
a
Costs adjusted for inflation using the Medical Care Consumer Price Index and all amounts are presented in January 2014 U.S. Dollars
b
Level change represents the average level change in patient out-of-pocket costs following the intervention point (February 2016)
c
Slope change represents the average monthly change in cost trend over the post-intervention period relative to the baseline trend
*
p <0.05